TABLE 1 Cumulative analysis of 187 patients with myelodysplastic syndrome treated with low-dose decitabinea
From the following article:
Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection
Jean-Pierre Issa
BACK TO ARTICLE| Outcome | No.(%) |
|---|---|
aSummary of outcomes in several phase II studies of decitabine in elderly patients with high-risk myelodysplastic syndrome.28 | |
| Toxic death | 12 (6) |
| Progressive disease | 33 (18) |
| Stable disease | 39 (16) |
| Hematologic improvement | 26 (14) |
| Partial response | 19 (10) |
| Complete response | 47 (25) |
| Not evaluable | 11 (6) |
| Total response | 92 (49) |
| Median survival | 15 months |
| Two-year survival rate | 34% |
